has function has role immunizes against disease immunizes recipient brain cancer Homo sapiens therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role brain cancer vaccine CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine https://github.com/vaccineontology/VO/issues/380 Ibrahim Seleznev 8842 Gene name: PROM1 Oliver He Jie Zheng 5107 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5107 Eliyas Asfaw A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. NCT: https://clinicaltrials.gov/ct2/show/NCT02049489 cancer vaccine therapeutic cancer vaccine